Description: "Hear an overview of recent results and potential scenarios that may impact the future of the ACA market. Review recent reported industry level profitability before transitioning to a discussion of how current market dynamics may influence the future profitability of this segment. Results from microsimulation economic models will be presented to help illuminate market shifts. Issues that will be explored include how ICRA availability might influence individual decision making, as well as how a move to level funding is impacting the small group market. By attending this session, you will: Understand the recent average and variation of industry performance in the ACA market segment. Describe current policy and market forces that are expected to impact this segment. Explain the range of market scenarios that may result due to these forces."

Description: Read this essay, which addresses the actuarial impact of mental health issues in retirement.

Description: Actuaries are increasingly being asked to incorporate Economic Scenario Generators into their work. Whether it be a Risk Neutral model for pricing or a Real-World version for Economic Capital modelling, using these tools can help produce a much more robust analysis. Unfortunately, these models and their underpinnings are also very complicated, which can lead to confusion. Come watch the presenters try to demystify some of this. In particular, they will address the following questions: • What is the difference between Real-World and Risk Neutral scenarios? • When should I use one or the other? • How are these models calibrated? • What are some of the misconceptions about these models? At the conclusion of the session, attendees will be able to: • Explain the difference between Real-World and a Risk Neutral scenarios • Understand the appropriate usage of both • Identify some of the calibration questions that go into developing an appropriate set of scenarios • Avoid some of the common misconceptions about these scenarios

Description: View the report on Modeling the Impact of the Great Unwinding on State Medicaid Programs

Description: The coming wave of biosimilars could have a major impact on prescription drug spend in coming years. The big event of Humira biosimilar launches in 2023 will be significant in determining that ultimate impact. Payers are making coverage decisions. The more biosimilars are utilized, the greater the potential savings. How will biosimilar adoption be maximized?

Description: Read this report, which is part of the series "Understanding and Managing Post-Retirement Risks", to learn more about the perspective of the individual with respects to long-term care, caregiving, and housing issues.

Description: Join us for an exciting session as Actuarial Innovation & Technology Strategic Research from the SOA's Research Institute unveils two recently published research reports: ""Unveiling the Life Insurers' Actuarial Transformation Journey and the Impact of Analytics"" and ""Exploring Revolutionary Advances in Underwriting: An Initial Assessment of Epigenetics, Medical Tests, and Wearables"". In the first report, we delve into the evolving landscape of life insurers' Actuarial Transformation efforts, shedding light on their future prospects and emphasizing emerging Advanced Analytics techniques. The second report serves as the inaugural installment of a series dedicated to identifying promising innovations for underwriters and actuaries, and it promises to alert the SOA to the latest developments. During this session, our presenters will provide an insightful overview of the key findings and key takeaways from both research reports. By the end of the session, attendees will gain a deeper understanding and appreciation for the invaluable research conducted in these areas.

Description: Milliman was engaged by the SOA to conduct two Accelerated Underwriting (AU) surveys, one of direct companies and another of reinsurers. The surveys explored actual results from 2019–2021 and expected results from 2022.

Description: The advent of emerging technologies such as blockchain, decentralized AI, and advanced privacy preserving techniques have created the possibility that billions of individuals may be able to maintain sovereignty and control of their own data. As data becomes increasingly valuable as the means of production for a variety of digital goods and services, this self-sovereignty of data may create a new economic framework of individualized data monetization. This session will explore the key factors, technologies and mega-trends in health and medicine aligning to drive this new economy and explore what the future may look like from a data valuation perspective as the current $120 billion secondary market for health data expands to include consented health and health-relevant data from more individuals, to the benefit of all individuals and the healthcare system as a whole.

Description: 2024 Underwriting Innovations Symposium